Come join others currently navigating treatment in our weekly Zoom Meetup! Register here: Tuesdays, 1pm ET.
Fill Out Your Profile to share more about you. Learn more...
Webinar: Corrective Breast Reconstruction: Getting the Results You Want Join us July 9, 2024 at 6pm ET. Register here.

Verzenio + fulvestrant increased OS in ER+/HER2+ MBC


I guess this could eventually mean a new first line for estrogen positive HER2+ patients. This was just a Phase 2 trial so I suppose there has to be a Phase 3 before it would become common in clinical use. Looks like they didn’t include Perjeta (pertuzumab) in this protocol, either.


In this phase II trial, abemaciclib + trastuzumab +/- fulvestrant numerically improved median OS in women with HR+, HER2+ ABC compared to SOC chemotherapy + trastuzumab.

LINK: Practice Update - Metastatic Breast Cancer Newsletter